Entrectinib is an oral TKI targeting NTRK, ROS1, and ALK fusions, approved by the FDA and EMA for ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors, including TC, in patients ≥ 12 years [56,57,58]. Here, ROS1 is linked to non-small cell lung carcinoma.